# Neuravi

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neuravi

- Industry: Medical Devices & Equipment
- Headquarters: Galway, Ireland
- Website: www.neuravi.com
- Total disclosed funding: $28M
- Latest round: Series B (Jun 17, 2015)
- Investors on record: 4

## About

Neuravi, Ltd. is a medical device company specializing in advanced solutions for treating acute ischemic stroke. Their products enhance the effectiveness of thrombectomy procedures, contributing to improved patient outcomes.Founded in 2009 and headquartered in Galway, Ireland, Neuravi, Ltd. focuses on developing innovative medical devices for stroke management. In April 2017, the company was acquired by Codman Neuro from its previous investors, including Delta Partners and EQT Life Sciences. The latest funding round was a Series B, secured in 2017, totaling EUR 19.00 mn, led by EQT Life Sciences.Neuravi, Ltd.'s CERENOVUS Stroke Solutions™ offers medical devices specifically designed for mechanical thrombectomy to treat acute ischemic strokes. Core products include the EMBOTRAP™ III Revascularization Device and the NIMBUS™ Geometric Clot Extractor, which effectively remove blood clots from the brain, ensuring restoration of blood flow. The primary users of these devices are healthcare professionals in hospitals and specialized stroke centers across Europe, the Middle East, and Africa (EMEA).For the year ending 2023, Neuravi, Ltd. reported revenue of EUR 47,274,686.70 and an EBITDA of EUR 13,377,759.60, primarily generated through direct sales to healthcare facilities and institutions requiring advanced stroke treatment devices.Neuravi, Ltd. is focused on expanding its product offerings and geographical reach. The company plans to introduce new products in the near future, specifically aimed at enhancing stroke intervention techniques. Additionally, they aim to penetrate new markets, particularly in the Asia-Pacific region, by 2025. The EUR 19.00 mn raised in the latest funding round will be utilized to support these initiatives and further strengthen their product development capabilities.

## Funding rounds

- Series B, Jun 17, 2015, $22M — Delta Partners, EQT Life Sciences, Fountain Healthcare Partners, Western Development Commission
- Series A, Jul 12, 2012, $6.4M — Delta Partners, Fountain Healthcare Partners

## Investors

- Delta Partners (https://capitalatlas.ai/funds/delta-partners) — Series A, Series B
- Fountain Healthcare Partners (https://capitalatlas.ai/funds/fountain-healthcare-partners) — Series A, Series B
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series B
- Western Development Commission (https://capitalatlas.ai/funds/western-development-commission) — Series B